Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis
…, DC Mastellos, S Metallidis… - The Journal of …, 2020 - Am Soc Clin Investig
Emerging data indicate that complement and neutrophils contribute to the maladaptive
immune response that fuels hyperinflammation and thrombotic microangiopathy, thereby …
immune response that fuels hyperinflammation and thrombotic microangiopathy, thereby …
Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the …
…, SG Giotaki, P Gargalianos, S Metallidis… - JAMA network …, 2020 - jamanetwork.com
Importance Severe acute respiratory syndrome coronavirus 2 infection has evolved into a
global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable …
global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable …
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
…, P Panagopoulos, V Petrakis, S Metallidis… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has
emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first …
emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first …
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
…, D Canario, E Fernández-Cruz, S Metallidis… - The Lancet, 2022 - thelancet.com
Background Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG)
to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific …
to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific …
Microbiological characteristics of bacteremias among COVID-19 hospitalized patients in a tertiary referral hospital in Northern Greece during the second epidemic …
…, I Gkeka, M Archonti, S Kati, S Metallidis… - FEMS …, 2021 - academic.oup.com
Northern Greece was struck by an intense second COVID-19 (coronavirus disease 2019)
epidemic wave during the fall of 2020. Because of the coinciding silent epidemic of multidrug-…
epidemic wave during the fall of 2020. Because of the coinciding silent epidemic of multidrug-…
[PDF][PDF] Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific symptoms,
but many develop severe symptoms associated with an excessive inflammatory response. …
but many develop severe symptoms associated with an excessive inflammatory response. …
Polyclonal Endemicity of Carbapenemase-Producing Klebsiella pneumoniae in ICUs of a Greek Tertiary Care Hospital
…, T Papadopoulos, M Polemis, S Metallidis… - Antibiotics, 2022 - mdpi.com
Carbapenemase-producing Klebsiella pneumoniae (CPKP) emerged in Greece in 2002 and
became endemic thereafter. Driven by a notable variability in the phenotypic testing results …
became endemic thereafter. Driven by a notable variability in the phenotypic testing results …
Vancomycin-resistant enterococci, colonizing the intestinal tract of patients in a university hospital in Greece
S Metallidis, M Chatzidimitriou, A Tsona… - Brazilian Journal of …, 2006 - SciELO Brasil
OBJECTIVE: Determine the prevalence of Vancomycin-resistant enterococci (VRE)
colonizing the intestinal tract of hospitalized patients and define risk factors. MATERIAL AND …
colonizing the intestinal tract of hospitalized patients and define risk factors. MATERIAL AND …
